Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
NCT03033446
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
HepatoCellular Carcinoma
Interventions
RADIATION:
Y-90 Radioembolization
DRUG:
Nivolumab
Sponsor
National Cancer Centre, Singapore